These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17078784)

  • 1. Attention-deficit/hyperactivity disorder: using P300 topography to choose optimal treatment.
    Sangal RB; Sangal JM
    Expert Rev Neurother; 2006 Oct; 6(10):1429-37. PubMed ID: 17078784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attention-deficit/hyperactivity disorder: use of cognitive evoked potential (P300) to predict treatment response.
    Sangal RB; Sangal JM
    Clin Neurophysiol; 2006 Sep; 117(9):1996-2006. PubMed ID: 16890481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attention-deficit/hyperactivity disorder: cognitive evoked potential (P300) amplitude predicts treatment response to atomoxetine.
    Sangal RB; Sangal JM
    Clin Neurophysiol; 2005 Mar; 116(3):640-7. PubMed ID: 15721078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged P300 latency in attention deficit hyperactivity disorder predicts poor response to imipramine.
    Sangal JM; Sangal RB; Persky B
    Clin Electroencephalogr; 1996 Oct; 27(4):191-201. PubMed ID: 9465283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Studies of evoked potentials in children with the syndrome of attention deficit and hyperactivity].
    Smeyers P
    Rev Neurol; 1999 Feb; 28 Suppl 2():S173-6. PubMed ID: 10778509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of agents used in attention-deficit/hyperactivity disorder.
    Wilens TE
    J Clin Psychiatry; 2006; 67 Suppl 8():32-8. PubMed ID: 16961428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Attention deficit hyperactivity disorder: pharmacological options that are not "Ritalin"].
    Shmueli D; Gross-Tsur V
    Harefuah; 2005 Aug; 144(8):572-6, 597. PubMed ID: 16146157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
    Niederhofer H
    Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
    [No Abstract]   [Full Text] [Related]  

  • 11. Event-related wave activity in the EEG provides new marker of ADHD.
    Alexander DM; Hermens DF; Keage HA; Clark CR; Williams LM; Kohn MR; Clarke SD; Lamb C; Gordon E
    Clin Neurophysiol; 2008 Jan; 119(1):163-79. PubMed ID: 18054279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs for treatment of ADHD.
    Treat Guidel Med Lett; 2006 Nov; 4(51):77-82. PubMed ID: 17039210
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of atomoxetine, desipramine, d-amphetamine and methylphenidate on impulsivity in juvenile rats, measured in a T-maze procedure.
    Bizot JC; David S; Trovero F
    Neurosci Lett; 2011 Feb; 489(1):20-4. PubMed ID: 21129437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder.
    Newcorn JH; Michelson D; Kratochvil CJ; Allen AJ; Ruff DD; Moore RJ;
    Pediatrics; 2006 Dec; 118(6):e1701-6. PubMed ID: 17101710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attention-deficit/hyperactivity disorder: cognitive evoked potential (P300) topography predicts treatment response to methylphenidate.
    Sangal RB; Sangal JM
    Clin Neurophysiol; 2004 Jan; 115(1):188-93. PubMed ID: 14706487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. If-then planning modulates the P300 in children with attention deficit hyperactivity disorder.
    Paul I; Gawrilow C; Zech F; Gollwitzer P; Rockstroh B; Odenthal G; Kratzer W; Wienbruch C
    Neuroreport; 2007 May; 18(7):653-7. PubMed ID: 17426593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical considerations for the diagnosis and treatment of ADHD in the managed care setting.
    Jensen PS
    Am J Manag Care; 2009 May; 15(5 Suppl):S129-40. PubMed ID: 19601688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
    Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drugs for attention deficit hyperactivity disorder].
    Montañés-Rada F; Gangoso-Fermoso AB; Martíínez-Granero MA
    Rev Neurol; 2009 May 1-15; 48(9):469-81. PubMed ID: 19396764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.